Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Journey Medical (DERM) Short-Term Debt issuances (2023)

Journey Medical (DERM) has disclosed Short-Term Debt issuances for 1 consecutive years, with $28.0 million as the latest value for Q1 2023.

  • For the quarter ending Q1 2023, Short-Term Debt issuances changed N/A year-over-year to $28.0 million, compared with a TTM value of $28.0 million through Dec 2023, changed N/A, and an annual FY2023 reading of $28.0 million, up 460.0% over the prior year.
  • Short-Term Debt issuances was $28.0 million for Q1 2023 at Journey Medical.
  • Across five years, Short-Term Debt issuances topped out at $28.0 million in Q1 2023 and bottomed at $28.0 million in Q1 2023.